Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets

Neoplasia

Volumn 7, Issue 1, 2005, Pages 7-16

  Hoelzinger, Dominique B ^a,b   Mariani, Luigi ^c   Wies, Joachim ^d   Woyke, Tanja ^e   Berens, Theresa J ^a   McDonough, Wendy S ^a   Sloan, Andrew ^f   Coons, Stephen W ^g   Berens, Michael E ^a,h  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^h NONE   (United States)

Author keywords

cDNA microarray; Expression profile; Glioma; Invasion; Tissue microarray

Indexed keywords

AUTOTAXIN; COMPLEMENTARY DNA; EPHRIN B3; GENE PRODUCT; PROTEIN; PROTEIN TYROSINE KINASE; RNA; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER INVASION; DNA MICROARRAY; GENE; GENE EXPRESSION; GENOTYPE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

EID: 13444294190     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04535     Document Type: Article

References (54)

1. Giese A, Bjerkvig R, Berens ME, and Westphal M (2003). Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21, 1624-1636.
2. Burger PC, Dubois PJ, Schold SC Jr, Smith KR Jr, Odom GL, Crafts DC, and Giangaspero F (1983). Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58, 159-169.
3. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, and Cavenee WK (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61, 215-225 (discussion, 226-219).
4. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, and Kononen J (2000). Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60, 6617-6622.
5. Ljubimova JY, Khazenzon NM, Chen Z, Neyman YI, Turner L, Riedinger MS, and Black KL (2001). Gene expression abnormalities in human glial tumors identified by gene array. Int J Oncol 8, 287-295.
6. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, and Hanash SM (2001). Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61, 6885-6891.
7. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, and Zhang W (2002). Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12, 108-116.
8. Kim S, Dougherty ER, Shmulevich L, Hess KR, Hamilton SR, Trent JM, Fuller GN, and Zhang W (2002). Identification of combination gene sets for glioma classification. Mol Cancer Ther 1, 1229-1236.
9. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, and Zhang W (1999). Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59, 4228-4232.
10. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, et al. (2003). Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63, 1602-1607.
11. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, Ponce F, Coons SW, Giese A, Seiler RW, and Berens ME (2001). Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells In vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 7, 2480-2489.
12. Kleihues P and Webster KC (2000). World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the Nervous System IARC Press, Lyon, France.
13. Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, Coons SW, Giese A, Moghaddam M, Seiler RW, and Berens ME (2001). Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res 61, 4190-4196.
14. Roche Molecular Biochemicals ME (2000). LightCycler Operator's Manual. Version 3.5. Roche Diagnostics GmbH, Mannheim D-68298, Germany.
15. Ivanov AI, Pero RS, Scheck AC, and Rofnanovsky AA (2002). Prostaglandin E(2)-synthesizing enzymes in fever: differential transcriptional regulation. Am J Physiol Regul Integr Comp Physiol 283, R1104-R1117.
16. Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, Beaudry C, Berens ME, and Loftus JC (2003). Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res 1, 323-332.
17. Zhang W, Wang H, Song SW, and Fuller GN (2002). Insulin-like growth factor binding protein 2: gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 12, 87-94.
18. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
19. Paulus W and Peiffer J (1989). Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64, 442-447.
20. Louis DN, Holland EC, and Cairncross JG (2001). Glioma classification: a molecular reappraisal. Am J Pathol 159, 779-786.
21. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, and DePinho RA (2001). Malignant glioma: genetics and biology of a grave matter. Genes Dev 15, 1311-1333.
22. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, et al. (2003). Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361-2373.
23. Rutka JT, Murakami M, Dirks PB, Hubbard SL, Becker LE, Fukuyama K, Jung S, Tsugu A, and Matsuzawa K (1997). Role of glial filaments in cells and tumors of glial origin: a review. J Neurosurg 87, 420-430.
24. Gladson CL (1999). The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58, 1029-1040.
25. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, Demuth T, and Berens ME (2003). Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116, 4409-4417.
26. Yamaguchi H, Tanaka F, Sadanaga N, Ohta M, Inoue H, and Mori M (2003). Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells. Int J Oncol 23, 1697-1702.
27. Buttiglieri S, Deregibus MC, Bravo S, Cassoni P, Chiarle R, Bussolati B, and Camussi G (2004). Role of PAX2 on apoptosis resistance and pro-invasive phenotype of Kaposi's sarcoma cells. J Biol Chem 279, 4136-4143.
28. Ishikawa S, Egami H, Kurizaki T, Akagi J, Tamori Y, Yoshida N, Tan X, Hayashi N, and Ogawa M (2003). Identification of genes related to invasion and metastasis in pancreatic cancer by cDNA representational difference analysis. J Exp Clin Cancer Res 22, 299-306.
29. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Huttelmaier S, Zavadil J, Cermak L, Bottinger EP, Singer RH, White JG, et al. (2002). Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 62, 6278-6288.
30. Giese A (2003). Glioma invasion-pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumor-suppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 88, 153-162.
31. Maidment SL (1997). The cytoskeleton and brain tumour cell migration. Anticancer Res 17, 4145-4149.
32. Roy P and Jacobson K (2004). Overexpression of profilin reduces the migration of invasive breast cancer cells. Cell Motil Cytoskelet 57, 84-95.
33. Speck O, Hughes SC, Noren NK, Kulikauskas RM, and Fehon RG (2003). Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature 421, 83-87.
34. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, and Weller M (2001). Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 21, 3360-3368.
35. Ahmed S, Lee J, Kozma R, Best A, Monfries C, and Lim L (1993). A novel functional target for tumor-promoting phorbol esters and lysophosphatidic acid. The p21rac-GTPase activating protein-chimaerin. J Biol Chem 268, 10709-10712.
36. Kozma R, Ahmed S, Best A, and Lim L (1996). The GTPase-activating protein n-chimaerin cooperates with Rac1 and Cdc42Hs to induce the formation of lamellipodia and filopodia. Mol Cell Biol 16, 5069-5080.
37. Wang Q, Xie Y, Du QS, Wu XJ, Feng X, Mei L, McDonald JM, and Xiong WC (2003). Regulation of the formation of osteoclastic actin rings by proline-rich tyrosine kinase 2 interacting with gelsolin. J Cell Biol 160, 565-575.
38. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, and Liotta LA (1992). Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267, 2524-2529.
39. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, and Lee HY (2002). Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19, 603-608.
40. Timar J, Raso E, Dome B, Ladanyi A, Banfalvi T, Gilde K, and Raz A (2002). Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin Exp Metastasis 19, 225-232.
41. Kennedy TE (2000). Cellular mechanisms of netrin function: long-range and short-range actions. Biochem Cell Biol 78, 569-575.
42. Carroll RS, Zhang J, Chauncey BW, Chantziara K, Frosch MP, and Black PM (1997). Apoptosis in astrocytic neoplasms. Acta Neurochir (Wien) 139, 845-850.
43. Bogler O and Weller M (2002). Apoptosis in gliomas, and its role in their current and future treatment. Front Biosci 7, e339-e353.
44. Kuriyama H, Lamborn KR, O'Fallon JR, Iturria N, Sebo T, Schaefer PL, Scheithauer BW, Buckner JC, Kuriyama N, Jenkins RB, et al. (2002). Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro-Oncology 4, 179-186.
45. Chicoine MR and Silbergeld DL (1995). The In vitro motility of human gliomas increases with increasing grade of malignancy. Cancer 75, 2904-2909.
46. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, and Meyermann R (1999). BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67, 763-768.
47. 2-terminal kinase activation. Cancer Res 63, 1093-1100.
48. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, and Rizzuto R (2002). A role for calcium in Bcl-2 action? Biochimie 84, 195-201.
49. 2+: a control point for apoptosis. Science 300, 135-139.
50. Fill M and Copello JA (2002). Ryanodine receptor calcium release channels. Physiol Rev 82, 893-922.
51. [51 ] Miyazaki T and Reed JC (2001). A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2, 493-500.
52. Mischel PS and Cloughesy TF (2003). Targeted molecular therapy of GBM. Brain Pathol 13, 52-61.
53. Rainov NG and Ren H (2003). Gene therapy for human malignant brain tumors. Cancer J 9, 180-188.
54. Giese A, Loo MA, Tran N, Haskett D, Coons SW, and Berens ME (1996). Dichotomy of astrocytoma migration and proliferation. Int J Cancer 67, 275-282.